6-Aminonicotinamide enhances the efficacy of 5-aminolevulinic acid-mediated photodynamic therapy for neuroblastoma.

ABSTRACT:

Background

Photodynamic therapy (PDT) utilizing 5-aminolevulinic acid (5-ALA) as a photosensitizing precursor is an approved treatment modality for several types of cancers. However, the increased generation of antioxidants in cancer cells renders them resistant to PDT. MYCN-amplified neuroblastoma shows increased production of reactive oxygen species (ROS) and relies on the glutathione redox system for ROS detoxification. We tested the effectiveness of combining 6-aminonicotinamide (6-AN), a glucose-6-phosphate dehydrogenase inhibitor that modulates nicotinamide adenine dinucleotide phosphate and glutathione redox balance, with PDT for treating neuroblastoma.

Methods

Cellular protoporphyrin IX (PpIX) accumulation, cell proliferation, morphological changes, induction of cell

SUBMITTER: Okamura SM 

PROVIDER: S-EPMC12648907 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature